N
Neuren Pharmaceuticals
Therapies for rare neurodevelopmental and brain disorders.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX: NEU) is an Australian biopharmaceutical company that develops therapies for serious neurological disorders. Founded in 2001, the company's research originates from Auckland University and focuses on conditions with limited or no approved treatment options. The company's business model centers on research and development, creating specialized drug assets and then partnering with larger pharmaceutical companies for late-stage development, distribution, and sales. A significant milestone was achieved in March 2023, when the U.S. Food and Drug Administration (FDA) approved DAYBUE® (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients aged two and older. This was the first-ever approved treatment for this rare genetic neurological disorder. Neuren has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide. This partnership generates revenue for Neuren through royalties and milestone payments. For instance, in 2023, DAYBUE's net sales reached USD 177 million in a partial launch year, and Neuren reported a full-year profit of AUD 157 million. Neuren's drug candidates are synthetic analogues of molecules naturally occurring in the brain that are involved in the biology of Insulin-like growth factor 1 (IGF-1). These orally administered drugs are designed to have a broad impact on the underlying abnormal biological processes in the brain, including reducing neuro-inflammation and restoring normal cell function. DAYBUE® is available as an oral solution and a powder for oral solution. The company's pipeline includes a second drug candidate, NNZ-2591 (ercanetide), which is in clinical development for several other neurodevelopmental disorders. It has shown positive results in Phase 2 trials for Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome. A Phase 3 trial for Phelan-McDermid syndrome is currently underway. These programs have received "orphan drug", "Fast Track", and "Rare Pediatric Disease" designations from the FDA. Neuren retains worldwide rights for NNZ-2591 for all indications except for Rett syndrome and Fragile X syndrome, which are licensed to Acadia.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2005
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
Neuren Pharmaceuticals in the Melbourne ecosystem
The Neuren Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuren Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuren Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
